Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions HEOR Analyses of Real-World Data Reveal Disparities in Outcomes In Females and Older Patients with Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif., May 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data arising from two... Read More

SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 5 employees, whose employment commenced in April and May, 2025, as a material inducement to their... Read More

Second Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 30 th , 2025 from 8:00 AM to 6:00 PM Pacific Time. The event will be held at... Read More

Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from MAPLE-HCM ( M etoprolol vs A ficamten in P atients with L VOT Obstruction on E xercise Capacity in HCM ), a... Read More

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European Society of Cardiology, taking place in Belgrade, Serbia from May 17, 2025 – May 20, 2025. Late Breaking Science Presentations Title: Efficacy and Safety of Aficamten in... Read More

SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 14, 2025 at 10:00 AM Pacific Time at the Company’s headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive... Read More

PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2025 SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial... Read More

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) to December 26, 2025. The FDA recently notified Cytokinetics... Read More

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following investor conferences in May: The Citizens Life Sciences Conference: Members of the management team will participate in a fireside chat on Wednesday, May 7, 2025 at 10:00 AM Eastern Time at the New York Hilton Midtown Hotel in New York, NY. 2025... Read More

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 6, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously... Read More

SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 15, 2025 it granted stock options to purchase an aggregate of 60,670 shares of common stock and 40,888 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 13 employees, whose employment commenced in March and April, 2025, as a material inducement to... Read More

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in a fireside chat at the 24 th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 2:15 PM Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media... Read More

Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to Care SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of EARTH-HCM ( E pidemiology, A wareness, R eal-world T reatment and H ealth Outcomes in HCM ), an online, open access, interactive public health education tool developed by... Read More

SOUTH SAN FRANCISCO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 14, 2025 it granted stock options to purchase an aggregate of 58,631 shares of common stock, 38,068 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 3,381 performance stock units (PSUs) that, if earned, will be settled in shares of common stock... Read More

New Analyses Related to Aficamten Expand on its Metabolism Pathways, Treatment Effect Associated with Combination Therapy with Disopyramide and Longer-Term Effect on Cardiac Structure and Function SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten , an investigational cardiac myosin inhibitor, and hypertrophic... Read More

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March: Leerink Global Biopharma Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat on Monday,... Read More

Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and China Topline Results from MAPLE-HCM Expected in Q2 2025 Company Provides 2025 Financial Guidance; ~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2024 SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 14, 2025 it granted stock options to purchase an aggregate of 23,337 shares of common stock and 15,153 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 6 employees, whose employment commenced in February 2025, as a material inducement to their... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The... Read More

Appointment Deepens Financial and Operational Expertise of Board as Company Approaches Potential Commercialization SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 4:40 PM Eastern Time. Interested parties may access the live webcast of the fireside chat... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2025 it granted stock options to purchase an aggregate of 64,587 shares of common stock, 41,939 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 6,066 performance stock units (PSUs) that, if earned, will be settled in shares of common stock... Read More

Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its seventh annual Communications Grant Program, intended to support increased communications, awareness building and community engagement. Five grants in the amount of... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF ( A ssessment of CK-586 in a M ulti-Center, B linded E valuation of Safety and Tolerability R esults in HFpEF ) is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial of CK-4021586 (CK-586) in patients with... Read More

PDUFA Target Action Date for Aficamten Set for September 26, 2025; Commercial Launch Preparations Underway for First Potential Approval Five-Year Aspirations Outline Corporate Strategies to Becoming Leading Muscle Biology Specialty Biopharma Company SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA. Interested parties may access the live... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate of 52,188 shares of common stock, 33,885 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 3,189 performance stock units (PSUs) that, if earned, will be settled in shares of common stock... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten , a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The MAA will now be reviewed by the Committee for Medicinal Products for Human... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten is a next-in-class cardiac myosin inhibitor for the... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 29, 2024 it granted stock options to purchase an aggregate of 34,515 shares of common stock and 22,410 restricted stock units (RSUs) that will be settled into shares of common stock upon vesting to 7 employees, whose employment commenced in November 2024, as a material inducement to their... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that COMET-HF ( C onfirmation of O mecamtiv M ecarbil E fficacy T rial in H eart F ailure), a confirmatory Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic heart failure (HF) with severely reduced ejection fraction, is open to enrollment. Omecamtiv mecarbil is a novel... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following December investor conferences: 7 th Annual Evercore ISI HealthconX Conference: Cytokinetics will participate in a fireside chat on Tuesday, December 3, 2024 at 9:35 AM Eastern Time at the Loews Coral Gables Hotel in Coral Gables, FL. 36 t h... Read More

PDUFA Target Action Date Set for September 26, 2025 SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for aficamten , a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The FDA assigned the NDA a... Read More

Approximately €70 Million in Upfront and Near-term Payments to Cytokinetics Up to €490 Million in Commercial Milestone Payments, with Tiered Royalties on Future Sales SOUTH SAN FRANCISCO, Calif. and BERLIN, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Bayer today announced they have entered into a collaboration and license agreement for the exclusive development and commercialization of... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from post-hoc analyses of GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes T hrough I mproving C ontractility in H eart F ailure), the Phase 3 cardiovascular outcomes clinical... Read More

Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life New Data from FOREST-HCM Demonstrate Aficamten Durably Reduces the Proportion of Patients Guideline Eligible for Septal Reduction Therapy Analyses of Real-World Data Reveal Cost of Care Differences in HCM Across Gender, Age and Race/Ethnicity SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 4:00 PM Greenwich Mean Time at The Waldorf Hilton Hotel in London, England. Interested parties may access the live webcast of the fireside chat by visiting the... Read More

Advancement of Fast Skeletal Muscle Troponin Activator Expands Pipeline of Muscle-Directed Drug Candidates SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose clinical study of CK-4015089 (CK-089) in healthy... Read More

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4 Plan to Advance CK-089, Fast Skeletal Muscle Troponin Activator, into First-In-Human Study in Q4 2024 ~$1.3 Billion in Cash, Cash Equivalents and Investments as of September 30, 2024 SOUTH SAN FRANCISCO,... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations at the American Heart Association Scientific Sessions 2024 taking place in Chicago, IL from November 16, 2024 - November 18, 2024. Aficamten Title : Modifiability of Post-Exercise Oxygen Uptake Recovery Patterns: A Substudy of the SEQUOIA-HCM Trial Presenter : Gregory D. Lewis,... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2024 it granted stock options to purchase an aggregate of 17,712 shares of common stock and 11,499 restricted stock units (RSUs) that will be settled into shares of common stock upon vesting to 7 employees, whose employment commenced in October 2024, as a material inducement to their... Read More

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 6, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The... Read More

NDA for Aficamten Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4 Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM Beyond The Heart” for Health Care Professionals... Read More

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2024 it granted stock options to purchase an aggregate of 88,653 shares of common stock and 57,558 restricted stock units (RSUs) that will be settled into shares of common stock upon vesting to 30 employees, whose employment commenced in September 2024, as a material inducement to... Read More

Company Leadership to Discuss Cardiac Myosin Modulation, Specialty Cardiology Programs and Commercial Launch Preparations SOUTH SAN FRANCISCO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host an Investor and Analyst Day on Wednesday, October 16, 2024 from 8:30 AM to 11:30 AM ET. The event, entitled “Heart Forward: Advancing Cardiac Myosin Modulation,” will... Read More

Responder Analyses Show Treatment with Aficamten Demonstrated Improvements on Multiple Assessments of Clinical Significance to Cardiologists Results Simultaneously Published in the Journal of the American College of Cardiology SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional analyses synthesizing data from SEQUOIA-HCM ( S afety, E... Read More

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM ( S afety, E fficacy, and Q uantitative U nderstanding of O bstruction I mpact of A ficamten in HCM ), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were presented at the Hypertrophic... Read More

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is November 4 th , 2024 SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the seventh annual Cytokinetics Communications Grant Program. The program will award five... Read More

Analyses of Effects of Aficamten on Key Clinical Outcomes from SEQUOIA-HCM to be Featured in Late Breaking Clinical Trial Presentation at HFSA SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on September 27, 2024 and one Late Breaking Clinical... Read More

Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a poster session... Read More

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two presentations at the 2024 American College of Clinical Pharmacology (ACCP) Annual Meeting in Bethesda, MD from September 8, 2024 – September 10, 2024. Title: A First-in-Human, Single & Multiple Ascending Dose Study of CK-4021586, A Novel Cardiac Myosin Inhibitor Presenter: Justin Lutz, Pharm. D.,... Read More

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 30, 2024 it granted stock options to purchase an aggregate of 51,039 shares of common stock, 33,140 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 14,603 performance stock units (PSUs) that, if earned, will be settled in shares of common stock... Read More

Data from Integrated Safety Analysis Across Three Clinical Trials Reinforces Robust Safety Profile of Aficamten Analysis from FOREST-HCM Demonstrates Successful Withdrawal of Standard of Care Medications in Patients with Obstructive HCM Treated with Aficamten Company to Host Conference Call and Webcast Tuesday, September 3rd at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics,... Read More

Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodeling by Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography, Symptom Relief and Improvement in Biomarkers with Aficamten Presentations Accompanied by Four Simultaneous Journal Publications Company to Host Conference Call and... Read More

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following investor conferences in September: Morgan Stanley 22 nd Annual Global Healthcare Conference: Cytokinetics will participate in a fireside chat on Wednesday, September 4, 2024 at 7:45 AM Eastern Time at the New York Marriott Marquis Hotel in New... Read More

Type B Meeting Held with FDA Related to Potential Risk Mitigation Strategies for Aficamten; Company Has Initiated Rolling NDA Submission FDA Cleared Protocol Amendment for FOREST-HCM Reducing Frequency of Echocardiographic Monitoring Required During Maintenance Treatment ~$1.4 Billion in Cash, Cash Equivalents and Investments as of June 30, 2024 SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics,... Read More

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 31, 2024 it granted stock options to purchase an aggregate of 44,887 shares of common stock and 29,149 restricted stock units (RSUs) that will be settled into shares of common stock upon vesting to 16 employees, whose employment commenced in July 2024, as a material inducement to their... Read More

Program Augments Existing Patient Advocacy and Professional Society Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is September 16 th , 2024 SOUTH SAN FRANCISCO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the Cytokinetics Corporate Giving Program. The program provides charitable donations to... Read More

SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 8, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The... Read More

Late Breaking Clinical Trial Presentations to Feature Additional Results from SEQUOIA-HCM Related to Patient-Reported Health Status, Cardiac Structure and Function and Biomarkers Analyses of Safety and Outcomes from FOREST-HCM Related to Withdrawal of Standard of Care Medications to be Presented SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced seven... Read More

SOUTH SAN FRANCISCO, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 28, 2024 it granted stock options to purchase an aggregate of 48,453 shares of common stock, 31,460 restricted stock units (RSUs), and 5,537 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in... Read More

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian participants. “We are conducting this Phase 1 bridging study to characterize the pharmacokinetics of aficamten in healthy Japanese adults... Read More

SOUTH SAN FRANCISCO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2024 it granted stock options to purchase an aggregate of 53,417 shares of common stock, 34,684 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 34,426 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon... Read More

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in June: Jefferies Global Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat on... Read More

SOUTH SAN FRANCISCO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 9,803,922 shares of its common stock at a price to the public of $51.00 per share. The gross proceeds to Cytokinetics from the offering, before offering expenses payable by Cytokinetics, were approximately $500 million. J.P. Morgan,... Read More

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,803,922 shares of its common stock at a price to the public of $51.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering... Read More

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500 million of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Cytokinetics expects to grant the... Read More

SOUTH SAN FRANCISCO, Calif. and NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Royalty Pharma plc (Nasdaq: RPRX) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle... Read More

SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) today, May 17 th , 2024 at the Mission Bay Conference Center in San Francisco. “We are proud to convene the CLIMB Research Symposium, a unique forum for the muscle biology community,... Read More

SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten at the European Society of Cardiology Congress 2024, taking place in London, UK from August 30, 2024 – September 2, 2024. Title: Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Substudy... Read More

Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During Treatment with Aficamten Results from Cardiopulmonary Exercise Testing Showed Improvement in Exercise Performance were Strongly Correlated to Other Measures of Clinical Improvement Company to Host Investor Event and Webcast Today at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE)... Read More

Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints; Results Consistent Across All Prespecified Subgroups Rapid and Sustained Improvements Observed in Symptoms and Function; No Treatment Interruptions Due to Low LVEF Company to Host Investor Event... Read More

Primary Results and Two Additional Analyses from SEQUOIA-HCM to be Presented in a Late-Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress Opened Enrollment to CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population with Obstructive HCM Announced Topline Data from the Phase 1 Study of CK-586; Phase 2 Clinical Trial to Begin in Q4 2024 SOUTH SAN FRANCISCO, Calif., May... Read More

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM ( C linical E valuation of D osing with A ficamten to R educe Obstruction in a Pediatric Population in HCM ), a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment. Aficamten is a next-in-class cardiac... Read More

Data Support Advancement to Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 Full Data from the Phase 1 Study to be Presented at a Medical Congress in 2H 2024 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced topline data from the Phase 1 study of CK-4021586 (CK-586). The study met its... Read More

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 15, 2024 at 10:00 AM Pacific Time at the Company’s headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive... Read More

SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 30, 2024 it granted stock options to purchase an aggregate of 29,646 shares of common stock and 17,012 shares of restricted stock units (RSUs) convertible into shares of common stock upon vesting to five new employees, whose employment commenced in April 2024, as a material inducement to their... Read More

SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) to discuss the primary results from SEQUOIA-HCM ( S afety, E fficacy, and Q uantitative U nderstanding of O bstruction I mpact of A ficamten in HCM ), which are being... Read More

SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference... Read More

Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Clinical Trial presentations relating to... Read More

SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM ( F ollow-up, O pen-Label, R esearch E valuation of S ustained T reatment with Aficamten in HCM ), the open label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy (HCM), at the 73 rd Annual American College of Cardiology (ACC)... Read More

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 29, 2024 it granted stock options to purchase an aggregate of 78,000 shares of common stock to five new employees, whose employment commenced in March 2024, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $70.11 per share,... Read More

SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 23 rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 2:15 PM Eastern Time. Interested parties may access the live webcast of this fireside chat by visiting the... Read More

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73 rd Annual Scientific Session (ACC.24) taking place in Atlanta, GA from April 6, 2024 – April 8, 2024. Title: 1075-11 - Efficacy and Safety of Aficamten in the First Cohort of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy... Read More

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March: Leerink Global Biopharma Conference: Robert I. Blum, President and Chief Executive Officer, Andrew Callos, Executive Vice President and Chief Commercial Officer, and Fady I. Malik, Executive Vice President of... Read More

SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 29, 2024 it granted stock options to purchase an aggregate of 28,500 shares of common stock to three new employees, whose employment commenced in February 2024, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $72.24 per... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day®. Rare Disease Day® is an international campaign elevating the awareness and public understanding of rare diseases. The initiative spotlights the... Read More

SOUTH SAN FRANCISCO, Calif., and ALBANY, Ga., and WASHINGTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), together with The Mended Hearts, Inc. and WomenHeart: The National Coalition for Women with Heart Disease, today announced the launch of ENACT: Empower, Navigate, Activate for Clinical Trials, an initiative designed to champion greater awareness and engagement in cardiovascular clinical... Read More

Topline Results from SEQUOIA-HCM Announced in December Showed Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint and Improvements in All Secondary Endpoints Company Plans to Submit New Drug Application for Aficamten to FDA in Q3 2024 and Marketing Authorization Application to EMA in Q4 2024 Primary Results from SEQUOIA-HCM Are Expected to be Presented at an Upcoming Medical Conference... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Oppenheimer 34 th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:40 AM Eastern Time. Interested parties may access the live webcast of the fireside chat... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its sixth annual Communications Grant Program, intended to support increased capacity in communications, awareness building and community engagement. Five grants in the amount of $20,000 each were awarded this year to patient advocacy organizations focused on the hypertrophic... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM ( F ollow-up, O pen-Label, R esearch E valuation of S ustained T reatment with Aficamten in HCM ), the open label extension clinical trial of aficamten in... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced an upcoming presentation at CMR 2024 taking place online and in person in London, UK from January 25-27, 2024. Title: Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The FOREST-HCM CMR Sub-study Presenter: Ahmad Masri, M.D., MS, Director of the... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 29, 2023 it granted stock options to purchase an aggregate of 6,150 shares of common stock to three new employees, whose employment commenced in December 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $83.49 per... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA. Interested parties may access the live... Read More

Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant and Clinically Meaningful Improvements in All Secondary Endpoints No Instances of Treatment Interruptions Due to Low LVEF Company to Host Conference Call and Webcast Today at 8:30 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif.,... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of its senior management will host an investor call at 8:30 AM Eastern Time on Wednesday, December 27, 2023 to discuss the topline results from SEQUOIA-HCM ( S afety, E fficacy, and Q uantitative U nderstanding of O bstruction I mpact of A ficamten in HCM ), the pivotal Phase 3 clinical trial... Read More

As Previously Announced, Reldesemtiv Had No Effect on the Primary Endpoint of Change from Baseline in ALSFRS-R or Key Secondary Endpoints Trial Discontinued in March 2023 Due to Futility Following Second Planned Interim Analysis Survey Reveals Site Personnel and Patients Have Favorable View of Trial Features to Reduce Burden of Participation SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics,... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2023 it granted stock options to purchase an aggregate of 25,350 shares of common stock to two new employees, whose employment commenced in November 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $33.48 per... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations at the 34 th International Symposium on ALS/MND taking place in Basel, Switzerland and online from December 6, 2023 - December 8, 2023. Oral Presentations Title : Site and Participant Perspectives on Participating in an ALS Trial Designed to Reduce Burden: COURAGE-ALS Presenter : Stacy... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2023 it granted stock options to purchase an aggregate of 22,350 shares of common stock to five new employees, whose employment commenced in October 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $34.86 per... Read More

On Track for Topline Results from SEQUOIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Obstructive HCM, in Late December Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten, Show Sustained Improvements in Clinical Efficacy Endpoints and No Treatment Interruptions for Low Ejection Fraction Initiated Enrollment in ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Non-Obstructive HCM... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in November: UBS BioPharma Conference on Wednesday, November 8, 2023 at 1:00 PM Eastern Time in a fireside chat with Fady I. Malik, Executive Vice President of Research & Development, and Andrew Callos, Executive Vice... Read More

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 2, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The... Read More

New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten, Show Sustained Improvements in Clinical Efficacy Endpoints and No Treatment Interruptions for Low Ejection Fraction Commercial Readiness Activities Leverage Insights from Market Research to Inform Market Segmentation and Patient-Centric Strategies New Pre-Clinical Data for CK-586 Shows Improved Diastolic Function and Reduced Cardiac Fibrosis in... Read More

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the baseline characteristics of patients randomized in SEQUOIA-HCM ( S afety, E fficacy, and Q uantitative U nderstanding of O bstruction I mpact of A ficamten in HCM ), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were... Read More

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a virtual Investor and Analyst Day on Thursday, October 19, 2023 from 8:30 AM to 11:30 AM ET. The event, entitled New Horizons in Hypercontractility, will feature presentations from senior leaders about the Company’s cardiac myosin inhibition programs in hypertrophic cardiomyopathy (HCM)... Read More

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 29, 2023 it granted stock options to purchase an aggregate of 5,700 shares of common stock to two new employees, whose employment commenced in September 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $29.46 per... Read More

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced upcoming presentations at the 2023 Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on October 6, 2023, and at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, taking place from October 6-9, 2023, both taking place in Cleveland, OH. 2023 HCMS Scientific Sessions... Read More

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 1 st , 2023 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the sixth annual Cytokinetics Communications Grant Program. The program... Read More

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in September: Morgan Stanley 21 st Annual Global Healthcare Conference on Monday, September 11, 2023 at 8:00 AM Eastern Time in a fireside chat with Robert I. Blum, President and Chief Executive Officer, and Fady I. Malik,... Read More

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that ACACIA-HCM ( A ssessment C omparing A ficamten to Placebo on C ardiac Endpoints I n A dults with Non-Obstructive HCM ), a Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), is open to enrollment. Aficamten is a next-in-class cardiac... Read More

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 31, 2023 it granted stock options to purchase an aggregate of 77,800 shares of common stock to 4 new employees, whose employment commenced in August 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $34.94 per share,... Read More

Completed Enrollment in SEQUOIA-HCM, Pivotal Phase 3 Trial of Aficamten in Obstructive HCM; On Track for Topline Results by the End of the Year Initiated Enrollment in MAPLE-HCM, a Phase 3 Clinical Trial Comparing Aficamten and Metoprolol in Obstructive HCM ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Non-Obstructive HCM, Expected to Start in September 2023 Company Reduces Projected Spending by Approximately... Read More

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 31, 2023 it granted stock options to purchase an aggregate of 60,200 shares of common stock to 3 new employees, whose employment commenced in July 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $33.35 per share, which... Read More

SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 3, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The... Read More

SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 30, 2023 it granted stock options to purchase an aggregate of 77,450 shares of common stock to 5 new employees, whose employment commenced in June 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $32.62 per share, which... Read More

First Phase 3 Trial Evaluating Monotherapy with a Cardiac Myosin Inhibitor Compared to Monotherapy with a Beta Blocker in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MAPLE-HCM ( M etoprolol vs A ficamten in P atients with L VOT Obstruction on E xercise Capacity in HCM) , a Phase 3... Read More

SOUTH SAN FRANCISCO, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2023 it granted stock options to purchase an aggregate of 76,800 shares of common stock to 7 new employees, whose employment commenced in May 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $37.69 per share, which... Read More

SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences: Jefferies Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat on Thursday, June 8, 2023... Read More

Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical Trial in Non-Obstructive HCM To Begin in 2H 2023 SOUTH SAN FRANCISCO, May 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated... Read More

SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one Late Breaking Clinical Trial presentation and two moderated ePoster presentations at Heart Failure 2023 an International Congress of the European Society of Cardiology taking place online and in Prague, Czech Republic from May 20, 2023 – May 23, 2023. Late Breaking Clinical Trial Title:... Read More

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose clinical study of CK-4021586 (CK-586). CK-586 is a cardiac myosin inhibitor in development for the potential treatment of patients with heart failure with... Read More

SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 9:00 AM Eastern Time at the New York Hilton Midtown in New York, NY. Interested parties may access the live webcast of this... Read More

SEQUOIA-HCM Nearing Completion of Enrollment; On Track for Results in Q4 2023 Additional Data from Cohort 4 of REDWOOD-HCM to be Presented in Late-Breaking Clinical Trial Session at European Society of Cardiology Heart Failure 2023 Congress Company to Reduce Spending by More Than 10% in 2023 to Maintain Over 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated... Read More

SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 10, 2023 at 10:00 AM Pacific Time at the Company’s headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive... Read More

SOUTH SAN FRANCISCO, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 28, 2023 it granted stock options to purchase an aggregate of 97,550 shares of common stock to 5 new employees, whose employment commenced in April 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $37.40 per share,... Read More

SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference... Read More

SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 at 10:00 AM Eastern Time. Interested parties may access the live webcast of this fireside chat by visiting the... Read More

SOUTH SAN FRANCISCO, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2023 it granted stock options to purchase an aggregate of 57,600 shares of common stock to 4 new employees, whose employment commenced in March 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $35.19 per share,... Read More

Company Plans to Discontinue the Phase 3 Clinical Trial of Reldesemtiv After Data Monitoring Committee Found No Effect on Primary or Key Secondary Endpoints Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Data Monitoring Committee (DMC) for COURAGE-ALS ( C linical O... Read More

SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the release of its inaugural Corporate Responsibility Report , outlining the Company's commitment to social and environmental responsibility, ethics and governance and patient and community engagement. “At Cytokinetics, being a responsible corporate citizen is a natural extension of our company values,... Read More

SOUTH SAN FRANCISCO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences: Oppenheimer 33 rd Annual Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, will present virtually on Monday, March 13, 2023 at 10:00 AM Eastern Time. Barclays Global Healthcare Conference:... Read More

Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive HCM, Supporting Advancement to Phase 3 Additional Results from FOREST-HCM Demonstrate Long-Term Treatment with Aficamten for 48 Weeks is Well-Tolerated and Associated with Sustained Treatment Effect Company to Host Investor Event and Conference Call on March 6, 2023 at 8:30 AM... Read More

SOUTH SAN FRANCISCO, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28, 2023 it granted stock options to purchase an aggregate of 21,450 shares of common stock to 5 new employees, whose employment commenced in February 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $43.36 per... Read More

Company Received Complete Response Letter from FDA for New Drug Application for Omecamtiv Mecarbil Data from Cohort 4 of REDWOOD-HCM to be Presented at the American College of Cardiology Scientific Sessions; Results Expected from SEQUOIA-HCM in Q4 2023 Second Interim Analysis of COURAGE-ALS Expected to Occur in Q2 2023 Company Provides 2023 Financial Guidance; More than 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif.,... Read More

Complete Response Letter States that GALACTIC-HF Alone Does not Establish Substantial Evidence of Effectiveness Sufficient for Approval Company Expects to Request Meeting with FDA to Discuss Potential Next Steps Cytokinetics to Host Conference Call and Webcast on March 1, 2023 at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the American College of Cardiology 72 nd Annual Scientific Session (ACC.23) taking place in New Orleans, LA from March 4, 2023 – March 6, 2023. Title: 1560-153 - Aficamten in Patients with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (REDWOOD-HCM Cohort 4)... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day® on February 28, 2023. Rare Disease Day® is an international campaign elevating the awareness and public understanding of rare diseases. The... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on March 1, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2023 it granted stock options to purchase an aggregate of 87,600 shares of common stock to 13 new employees, whose employment commenced in January 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $42.48 per... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its fifth annual Communications Grant Program, intended to support communications, awareness building and community engagement for nonprofit organizations serving the patient community. Five grants in the amount of $20,000 each were awarded this year to patient advocacy organizations... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 30, 2022 it granted stock options to purchase an aggregate of 130,000 shares of common stock to 6 new employees, whose employment commenced in December 2022, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $45.82 per... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 AM Pacific Time at the Westin St. Francis Hotel in San Francisco. Interested parties may access the live webcast of this presentation... Read More

PDUFA Target Action Date is February 28, 2023 Cytokinetics to Host Conference Call and Webcast on December 14, 2022 at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 8 to 3 that the benefits of omecamtiv mecarbil do not... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) posted briefing documents for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to review the New Drug Application (NDA) for omecamtiv mecarbil, an investigational selective, small molecule cardiac myosin activator for the treatment of... Read More

Advancement of Novel Cardiac Troponin Activator Expands Cardiovascular Franchise for Conditions Associated with Impaired Cardiac Contractility SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose clinical study of... Read More